Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients

A. Calcagno, L. Marinaro, S. Nozza, C. Aldieri, A. Carbone, V. Ghisetti, A. Trentalange, A. D'Avolio, A. Castagna, G. Di Perri, S. Bonora

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Etravirine is a non-nucleoside reverse transcriptase inhibitor used in combination with other antiretrovirals for the treatment of HIV infection. Given previous conflicting results aim of this study was to investigate whether etravirine plasma exposure was associated with virological outcome. Adult HIV-positive patients starting etravirine with detectable HIV viral loads were included if highly adherent (10 copies/mL (3.11-4.91), respectively. Darunavir/ritonavir (n = 21, 35.6%) and raltegravir plus maraviroc (n = 33, 55.9%) were the most common associated antiretrovirals. 240 trough samples were available (3-7 per patient); etravirine trough concentrations (Ctrough) and weighted genotypic inhibitory quotients (wgIQ) were 426 ng/mL (266-763) and 408 ng/mL/mutation (227-663), respectively. Virological success was observed in 49 patients (83.1%). Genotypic sensitivity of associated drugs (GSS) ≥2 (p = 0.03), etravirine Ctrough >300 ng/mL (p = 0.02) and etravirine wgIQ >276 ng/mL/mutation (p = 0.02) were associated with virological success; at multivariate Cox proportional analysis etravirine wgIQ

Original languageEnglish
Pages (from-to)44-47
Number of pages4
JournalAntiviral Research
Volume108
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

etravirine
HIV
Ritonavir
Mutation
Reverse Transcriptase Inhibitors
Viral Load
HIV Infections

Keywords

  • Etravirine
  • Experienced patients
  • Inhibitory quotient
  • Pharmacokinetics
  • Resistance

ASJC Scopus subject areas

  • Virology
  • Pharmacology
  • Medicine(all)

Cite this

Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. / Calcagno, A.; Marinaro, L.; Nozza, S.; Aldieri, C.; Carbone, A.; Ghisetti, V.; Trentalange, A.; D'Avolio, A.; Castagna, A.; Di Perri, G.; Bonora, S.

In: Antiviral Research, Vol. 108, No. 1, 2014, p. 44-47.

Research output: Contribution to journalArticle

Calcagno, A, Marinaro, L, Nozza, S, Aldieri, C, Carbone, A, Ghisetti, V, Trentalange, A, D'Avolio, A, Castagna, A, Di Perri, G & Bonora, S 2014, 'Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients', Antiviral Research, vol. 108, no. 1, pp. 44-47. https://doi.org/10.1016/j.antiviral.2014.05.009
Calcagno, A. ; Marinaro, L. ; Nozza, S. ; Aldieri, C. ; Carbone, A. ; Ghisetti, V. ; Trentalange, A. ; D'Avolio, A. ; Castagna, A. ; Di Perri, G. ; Bonora, S. / Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. In: Antiviral Research. 2014 ; Vol. 108, No. 1. pp. 44-47.
@article{88537ca592134a7abf34b5a889e0a46e,
title = "Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients",
abstract = "Etravirine is a non-nucleoside reverse transcriptase inhibitor used in combination with other antiretrovirals for the treatment of HIV infection. Given previous conflicting results aim of this study was to investigate whether etravirine plasma exposure was associated with virological outcome. Adult HIV-positive patients starting etravirine with detectable HIV viral loads were included if highly adherent (10 copies/mL (3.11-4.91), respectively. Darunavir/ritonavir (n = 21, 35.6{\%}) and raltegravir plus maraviroc (n = 33, 55.9{\%}) were the most common associated antiretrovirals. 240 trough samples were available (3-7 per patient); etravirine trough concentrations (Ctrough) and weighted genotypic inhibitory quotients (wgIQ) were 426 ng/mL (266-763) and 408 ng/mL/mutation (227-663), respectively. Virological success was observed in 49 patients (83.1{\%}). Genotypic sensitivity of associated drugs (GSS) ≥2 (p = 0.03), etravirine Ctrough >300 ng/mL (p = 0.02) and etravirine wgIQ >276 ng/mL/mutation (p = 0.02) were associated with virological success; at multivariate Cox proportional analysis etravirine wgIQ",
keywords = "Etravirine, Experienced patients, Inhibitory quotient, Pharmacokinetics, Resistance",
author = "A. Calcagno and L. Marinaro and S. Nozza and C. Aldieri and A. Carbone and V. Ghisetti and A. Trentalange and A. D'Avolio and A. Castagna and {Di Perri}, G. and S. Bonora",
year = "2014",
doi = "10.1016/j.antiviral.2014.05.009",
language = "English",
volume = "108",
pages = "44--47",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients

AU - Calcagno, A.

AU - Marinaro, L.

AU - Nozza, S.

AU - Aldieri, C.

AU - Carbone, A.

AU - Ghisetti, V.

AU - Trentalange, A.

AU - D'Avolio, A.

AU - Castagna, A.

AU - Di Perri, G.

AU - Bonora, S.

PY - 2014

Y1 - 2014

N2 - Etravirine is a non-nucleoside reverse transcriptase inhibitor used in combination with other antiretrovirals for the treatment of HIV infection. Given previous conflicting results aim of this study was to investigate whether etravirine plasma exposure was associated with virological outcome. Adult HIV-positive patients starting etravirine with detectable HIV viral loads were included if highly adherent (10 copies/mL (3.11-4.91), respectively. Darunavir/ritonavir (n = 21, 35.6%) and raltegravir plus maraviroc (n = 33, 55.9%) were the most common associated antiretrovirals. 240 trough samples were available (3-7 per patient); etravirine trough concentrations (Ctrough) and weighted genotypic inhibitory quotients (wgIQ) were 426 ng/mL (266-763) and 408 ng/mL/mutation (227-663), respectively. Virological success was observed in 49 patients (83.1%). Genotypic sensitivity of associated drugs (GSS) ≥2 (p = 0.03), etravirine Ctrough >300 ng/mL (p = 0.02) and etravirine wgIQ >276 ng/mL/mutation (p = 0.02) were associated with virological success; at multivariate Cox proportional analysis etravirine wgIQ

AB - Etravirine is a non-nucleoside reverse transcriptase inhibitor used in combination with other antiretrovirals for the treatment of HIV infection. Given previous conflicting results aim of this study was to investigate whether etravirine plasma exposure was associated with virological outcome. Adult HIV-positive patients starting etravirine with detectable HIV viral loads were included if highly adherent (10 copies/mL (3.11-4.91), respectively. Darunavir/ritonavir (n = 21, 35.6%) and raltegravir plus maraviroc (n = 33, 55.9%) were the most common associated antiretrovirals. 240 trough samples were available (3-7 per patient); etravirine trough concentrations (Ctrough) and weighted genotypic inhibitory quotients (wgIQ) were 426 ng/mL (266-763) and 408 ng/mL/mutation (227-663), respectively. Virological success was observed in 49 patients (83.1%). Genotypic sensitivity of associated drugs (GSS) ≥2 (p = 0.03), etravirine Ctrough >300 ng/mL (p = 0.02) and etravirine wgIQ >276 ng/mL/mutation (p = 0.02) were associated with virological success; at multivariate Cox proportional analysis etravirine wgIQ

KW - Etravirine

KW - Experienced patients

KW - Inhibitory quotient

KW - Pharmacokinetics

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=84902003904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902003904&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2014.05.009

DO - 10.1016/j.antiviral.2014.05.009

M3 - Article

C2 - 24861522

AN - SCOPUS:84902003904

VL - 108

SP - 44

EP - 47

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 1

ER -